

## Daily News

Published by :



DAY 2

News  
AT A GLANCEPharma MacTech &  
LabNext showcasing...

▶ Page No. 14

Indian drug industry  
eyes global leadership...

▶ Page No. 16

India's bulk drug  
industry going bold...

▶ Page No. 19

Reimagining India's  
pharma exports...

▶ Page No. 24

Powering healthcare, connecting markets:  
India showcases innovation & global  
partnerships at iPHEX, MedTech Expo 2025

OUR BUREAU, MUMBAI

THE 11th edition of the International Exhibition on Pharmaceuticals and Healthcare (iPHEX 2025) and 2nd edition of India MedTech Expo 2025 opened at Bharat Mandapam, New Delhi, spotlighting India's stature as the

"Pharmacy of the World" and showcasing cutting-edge innovations shaping the future of pharmaceuticals and healthcare.

Inaugurated by Commerce & Industry Minister Piyush Goyal on September 4, the event underscored India's commitment to delivering affordable, high-quality medicines

and fostering deeper global collaborations to strengthen healthcare systems worldwide.

The three-day iPHEX 2025 is being organized by Pharmexcil under the Ministry of Commerce & Industry. It is being held alongside the India MedTech Expo 2025, organized by

CONTINUED ON p4▶

## MALTITOL

The Ready-to-use Natural  
Sugar Free SweetenerIMPROVES PATIENT'S  
HEALTH & COMPLIANCE

- ✓ Safe for Diabetics
- ✓ Children
- ✓ Pregnant Women
- ✓ Has NO Bitter after taste



PIOMA  
chemicals  
—Innovating Through Excellence—



+91-22-45212000 / 2001



products@pioma.net

for further information contact



## Will boom in global capability centres make India global hub for pharma and medtech research and innovation?

*THE boom in Global Capability Centres (GCCs) is rapidly transforming India from a “support base” into a strategic innovation engine for pharma and medtech. Nearly half of the world’s top 50 life sciences companies have set up GCCs in India in just the past five years. GCCs in India handle 45% of global drug discovery and development mandates, 60% of regulatory affairs, and 54% of medical affairs for their parent companies. They are leading clinical trials, pharmacovigilance, digital therapeutics, and real-world evidence analytics, often powered by AI.*

*Here are pharma honchos’ views on the strategic shift occurring due to the rise of GCCs in India’s pharma and medtech sectors.*



“THE boom in GCCs is positioning India as a serious contender to become a global hub for pharma and medtech research. With access to a vast and highly skilled talent pool, robust digital infrastructure, and cost-effective innovation ecosystems, GCCs are no longer limited to being support arms, they are evolving into strategic engines of R&D and innovation. These centres are enabling global companies to conduct advanced clinical research, accelerate drug discovery pipelines, and foster cross-border collaborations at an unprecedented scale. By integrating cutting-edge technologies such as AI, data analytics, and IoT, GCCs are also re-

shaping how healthcare solutions are designed, tested, and delivered. What was once seen as a back-office function is now transforming into the nerve centre of innovation. As global players continue to place their confidence in India’s expertise, it is evident that the country is not just participating but actively leading. The momentum is clear; India is on track to drive the future of pharma and medtech research.

**Dr Sanjay Agrawal**, Scientific Advisor of Alkomex GBN Pharma Group U.S.A.

“INDIA’S 1,700+ GCCs, including many in pharma and medtech, are already contributing significantly to R&D and innovation. With a strong talent pool, cost advantages, and growing expertise in digital health and AI-enabled drug discovery, India is increasingly well positioned to become a global hub for pharmaceutical and medtech breakthroughs. This momentum is visible at industry events such as IPHEX and Bharat Health Global Expo.



**Dr. Govind Pandey**, Director, Gamp Technologies Pvt Ltd